1. Scrip
  2. >>Therapy Areas

Ipsen To File Cabozantinib For Liver Cancer In 1H 2018

 
• By Lucie Ellis-Taitt

Exelixis and Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer. 

Cirrhosis
Ipsen to file cabozantinib for liver cancer in Europe after Positive Phase III

Ipsen will file cancer therapy cabozantinib in Europe for the treatment of advanced hepatocellular carcinoma (HCC) during the first half of next year on the back of positive data from the Phase III CELESTIAL trial; its partner Exelixis will file a supplemental new drug application for cabozantinib in the US for advanced HCC in the first quarter of 2018. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.